Serratia infection laboratory findings: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) Created page with "__NOTOC__ {{Serratia infection}} (((CMG}} ==Overview== ==Laboratory Findings== ==Culture Growth== According to the Centers for Disease Control and Prevention (CDC), the follow..." |
YazanDaaboul (talk | contribs) No edit summary |
||
| (9 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Serratia infection}} | {{Serratia infection}} | ||
{{CMG}} | |||
==Overview== | ==Overview== | ||
Diagnosis of ''Serratia'' infection is made by growth of ''Serratia'' in culture media. Other laboratory findings are non-specific. | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Laboratory findings may be non-specific and depend on the site of infection. | |||
==Culture Growth== | ==Culture Growth== | ||
According to the Centers for Disease Control and Prevention (CDC), the following procedure should be followed to properly culture | ===Procedure=== | ||
According to the Centers for Disease Control and Prevention (CDC), the following procedure should be followed to properly culture ''Serratia'':<ref> Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/pdf/0122.pdf. Accessed on January 5 2016</ref> | |||
*Biosafety Level: 2 | |||
*Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP) | *Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP) | ||
*Growth Conditions: | *Growth Conditions: | ||
| Line 18: | Line 22: | ||
:*Incubate inverted phase at 35 °C (95 °F) for 18-24 hours | :*Incubate inverted phase at 35 °C (95 °F) for 18-24 hours | ||
===MIC Results and Interpretation=== | ===MIC Results and Interpretation=== | ||
The following table demonstrates the MIC results following ''Serratia'' culture/antibiogram and interpretation | The following table demonstrates the minimum inhibitory concentration (MIC) results following ''Serratia'' culture/antibiogram and interpretation: | ||
{| {{table}} | {| {{table}} | ||
| align="center" style="background:#f0f0f0;"|'''MIC (µg/ml) Results and Interpretation | | align="center" colspan="3" style="background:#f0f0f0;"|'''MIC (µg/ml) Results and Interpretation''' | ||
|- | |- | ||
| Drug||MIC||Interpretation | | align="center" style="background:#f0f0f0;"|'''Drug'''||align="center" style="background:#f0f0f0;"|'''MIC'''||align="center" style="background:#f0f0f0;"|'''Interpretation''' | ||
|- | |- | ||
| Amikacin||2||S | | Amikacin||2||S | ||
| Line 78: | Line 80: | ||
| Trimethoprim/Sulfamethoxazole (TMP - SMX)||2||S | | Trimethoprim/Sulfamethoxazole (TMP - SMX)||2||S | ||
|} | |} | ||
<sup><nowiki>* Reflects MIC of first component</nowiki><br> | |||
<nowiki>** Screen for metallo-beta-lactamase production</nowiki><ref name="pmid23731823">{{cite journal| author=Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ et al.| title=New Delhi metallo-β-lactamase-producing Enterobacteriaceae, United States. | journal=Emerg Infect Dis | year= 2013 | volume= 19 | issue= 6 | pages= 870-8 | pmid=23731823 | doi=10.3201/eid1906.121515 | pmc=PMC3713825 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23731823 }} </ref><br> | |||
<nowiki>*** Based on FDA break points</nowiki><br> | |||
Abbreviations: MIC=Minimum inhibitory concentration; I=Intermediate; R=Resistant; S=Susceptible<br></sup> | |||
<sup>Table adapted from Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention.<ref> Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/pdf/0122.pdf. Accessed on January 5 2016</ref></sup> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 21:52, 6 February 2016
|
Serratia infection Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Serratia infection laboratory findings On the Web |
|
American Roentgen Ray Society Images of Serratia infection laboratory findings |
|
Risk calculators and risk factors for Serratia infection laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Diagnosis of Serratia infection is made by growth of Serratia in culture media. Other laboratory findings are non-specific.
Laboratory Findings
Laboratory findings may be non-specific and depend on the site of infection.
Culture Growth
Procedure
According to the Centers for Disease Control and Prevention (CDC), the following procedure should be followed to properly culture Serratia:[1]
- Biosafety Level: 2
- Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)
- Growth Conditions:
- Temperature: 35 °C (95 °F)
- Atmosphere: Aerobic
- Procedure
- Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)
- Open vial aseptically to avoid contamination
- Using a sterile loop, remove a small amount of frozen isolate from the top of the vial
- Aseptically transfer the loop to BAP
- Use streak plate method to isolate single colonies
- Incubate inverted phase at 35 °C (95 °F) for 18-24 hours
MIC Results and Interpretation
The following table demonstrates the minimum inhibitory concentration (MIC) results following Serratia culture/antibiogram and interpretation:
| MIC (µg/ml) Results and Interpretation | ||
| Drug | MIC | Interpretation |
| Amikacin | 2 | S |
| Amoxicillin/Clavulanic Acid * | > 32 | R |
| Ampicillin | > 32 | R |
| Ampicillin/Sulbactam | > 32 | R |
| Aztreonam | 16 | R |
| Cefazolin | > 32 | R |
| Cefepime | ≤ 0.5 | S |
| Cefotaxime | ≤ 1 | S |
| Cefoxitin | 2 | S |
| Ceftazidime | 1 | S |
| Ceftriaxone | ≤ 1 | S |
| Ciprofloxacin | ≤ 0.12 | S |
| Colistin | > 4 | _ |
| Doripenem | _ | _ |
| Ertapenem | > 16 | R |
| Gentamicin | 0.5 | S |
| Imipenem | > 32 | R |
| Imipenem + chelators ** | _ | _ |
| Levofloxacin | ≤ 0.25 | S |
| Meropenem | > 16 | R |
| Piperacillin/Tazobactam * | 2 | S |
| Polymyxin B | > 4 | _ |
| Tetracycline | 8 | I |
| Tigecycline *** | 1 | S |
| Tobramycin | 1 | S |
| Trimethoprim/Sulfamethoxazole (TMP - SMX) | 2 | S |
* Reflects MIC of first component
** Screen for metallo-beta-lactamase production[2]
*** Based on FDA break points
Abbreviations: MIC=Minimum inhibitory concentration; I=Intermediate; R=Resistant; S=Susceptible
Table adapted from Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention.[3]
References
- ↑ Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/pdf/0122.pdf. Accessed on January 5 2016
- ↑ Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ; et al. (2013). "New Delhi metallo-β-lactamase-producing Enterobacteriaceae, United States". Emerg Infect Dis. 19 (6): 870–8. doi:10.3201/eid1906.121515. PMC 3713825. PMID 23731823.
- ↑ Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/pdf/0122.pdf. Accessed on January 5 2016